TechNews

Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease`

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at

Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could offer advantages over other drugs currently available for…

science

Sources

Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease` · TechNews